Cholinergic System Neurodegeneration: Novel Pharmacotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 191
Special Issue Editors
Interests: basal forebrain cholinergic neurons; neurotoxicity; environmental pollutants; cognitive disorders
Special Issue Information
Dear Colleagues,
This Special Issue, entitled “Cholinergic System Neurodegeneration: Novel therapies”, will mainly focus on the molecular, structural, neurochemical, pathological, and behavioral studies of the cholinergic system’s neurodegeneration, its impact on disease, and novel therapies used to avoid them.
Acetylcholine was the first neurotransmitter identified by the studies of Henry Dale and Otto Loewi in 1936, which discovered chemical neurotransmission and afterwards the complex regulation of the cholinergic system and its functions. Cholinergic transmission regulates many functions peripherally (cardiovascular, gastrointestinal, respiratory, and reproductive systems, among others) and on the central nervous system (affective, memory, learning, and sleep regulation, among others), and its disruption is involved in different harmful neuropathologies.
As Guest Editor, I would be very pleased if you contributed to this Special Issue with either an original research paper or a focused review with emphasis on cholinergic system neurodegeneration and potential therapeutic approaches.
Prof. Dr. Javier del Pino
Dr. Paula Moyano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cholinergic system
- neurodegeneration
- acetylcholine
- cholinergic neurons
- cholinergic pathologies
- therapeutic approaches
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
